Drug intelligence / Profile preview

PM-014

Development stage
Preclinical
Lead developer
PharmAbcine
Modality
Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

PM-014 is a standardized **botanical herbal extract** derived from the traditional Korean medicine formula Chung-Sang-Bo-Ha-Tang and simplified from the original 18-herb prescription to a 7-herb formulation to improve reproducibility and standardization. It has been investigated primarily in academic Korean medicine research for inflammatory and fibrotic respiratory disorders, including chronic obstructive pulmonary disease, radiation-induced pneumonitis and pulmonary fibrosis, and particulate matter-induced lung inflammation. The available literature supports a **broad anti-inflammatory and immunomodulatory mechanism** rather than a single defined molecular target, with reported suppression of inflammatory cell recruitment into the lung and reduction of pro-inflammatory cytokines such as TNF-α and IL-6. No clear commercial brand name, approved product status, or single pharmaceutical company sponsor is evident from the provided context.

Other names
Chung-Sang-Bo-Ha-Tang-derived standardized herbal extractstandardized herbal formula derived from Chung-Sang-Bo-Ha-TangCSBHT-derived herbal extract
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)

Beyond the preview

Go deeper on PM-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PM-014.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call